ISCT22: Orgenesis looks to simplify, lower costs of providing CGT therapies
Personalized cell and gene therapies (CGTs) offer the potential to address the most challenging diseases, Vered Caplan, CEO of biotech company Orgenesis, told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco. However, several factors make CGTs complex, expensive, and difficult to bring to market, including small/personalized batch production and the fact that everything must be conducted in a very sterile environment. Read More
ISCT22: BroadOak’s Poltilove remains bullish on CGT market despite downturn
Bryan Poltilove, partner at BroadOak Capital Partners, spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco about how BroadOak’s medium- to long-term investment strategy sees “great science” happening in the sector that’s improving productivity and advancing cell and gene therapies (CGTs), biologics, and other modalities. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
